Pacific Island 'Awa (Kava) extracts, but not isolated kavalactones, promote proinflammatory responses in model mast cells

Phytotherapy Research

Volumn 26, Issue 12, 2012, Pages 1934-1941

  Shimoda, Lori M N ^a   Park, Christy ^a   Stokes, Alexander J ^b   Gomes, Henry Halenani ^a   Turner, Helen ^a,b  

^a CHAMINADE UNIVERSITY OF HONOLULU   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

kava; kava dermopathy; kavalactones; mast cells; Piper methysticum

Indexed keywords

CALCIUM; DIHYDROMETHYSTICIN; KAVA EXTRACT; KAVALACTONE; KAWAIN; METHYSTICIN; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DERMATITIS; HIBISCUS; HIBISCUS TILIACEUS; INFLAMMATION; MAST CELL; MOLECULAR PATHOLOGY; MUCILAGE; NONHUMAN; PACIFIC ISLANDS; PHYSICAL CHEMISTRY; PIPER METHYSTICUM; PLANT PHYSIOLOGY; RAT;

ADULT; AGED; ANIMALS; CALCIUM; CELL LINE; FEMALE; HIBISCUS; HUMANS; INFLAMMATION MEDIATORS; KAVA; LACTONES; MALE; MAST CELLS; MIDDLE AGED; PLANT EXTRACTS; PLANT MUCILAGE; RATS;

HIBISCUS TILIACEUS; PIPER METHYSTICUM;

EID: 84871296503     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4652     Document Type: Article

References (36)

1. Abraham SN, St John AL,. 2010. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10: 440-452.
2. Balick MJ, Lee R,. 2002. Traditional use of sakau (kava) in Pohnpei: lessons for integrative medicine. Altern Ther Health Med 8: 96-98.
3. Bilia AR, Scalise L, Bergonzi MC, Vincieri FF,. 2004. Analysis of kavalactones from Piper methysticum (kava-kava). J Chromatogr B Analyt Technol Biomed Life Sci 812: 203-214.
4. Brown AC, Onopa J, Holck P, et al,. 2007. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol (Phila) 45: 549-556.
5. Brunton R,. 1988. A harmless substance? Anthropological aspects of kava in the South Pacific. In Kava: Use and Abuse in Australia and the South Pacific. Monograph No. 5, National Drug and Alcohol Research Centre: Sydney.
6. Cote CS, Kor C, Cohen J, Auclair K,. 2004. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 322: 147-152.
7. Fu PP, Xia Q, Guo L, Yu H, Chan PC,. 2008. Toxicity of kava kava. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 26: 89-112.
8. Galli SJ, Tsai M,. 2010. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 40: 1843-1851.
9. Gounder R,. 2006. Kava consumption and its health effects. Pac Health Dialog 13: 131-135.
10. Grace R,. 2005. Kava-induced urticaria. J Am Acad Dermatol 53: 906.
11. Guro-Razuman S, Anand P, Hu Q, Mir R,. 1999. Dermatomyositis-like illness following kava-kava ingestion. J Clin Rheumatol 5: 342-345.
12. Harvima IT, Nilsson G, Suttle MM, Naukkarinen A,. 2008. Is there a role for mast cells in psoriasis? Arch Dermatol Res 300: 461-478.
13. Jani GK, Shah DP,. 2008. Evaluation of mucilage of Hibiscus rosasinensis Linn as rate controlling matrix for sustained release of diclofenac. Drug Dev Ind Pharm 34: 807-816.
14. Jappe U, Franke I, Reinhold D, Gollnick HP,. 1998. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 38: 104-106.
15. Kava R,. 2001. The adverse effects of kava. Pac Health Dialog 8: 115-118.
16. Kohda F, Koga T, Uchi H, Urabe K, Furue M,. 2002. Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes. J Dermatol Sci 28: 34-41.
17. Kubatova A, Miller DJ, Hawthorne SB,. 2001. Comparison of subcritical water and organic solvents for extracting kava lactones from kava root. J Chromatogr A 923: 187-194.
18. Lude S, Torok M, Dieterle S, Jaggi R, Buter KB, Krahenbuhl S,. 2008. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 15: 120-131.
19. Matsuda H, Hirata N, Kawaguchi Y, et al,. 2006. Melanogenesis stimulation in murine B16 melanoma cells by Kava (Piper methysticum) rhizome extract and kavalactones. Biol Pharm Bull 29: 834-837.
20. Middleton E, Jr., Kandaswami C, Theoharides TC,. 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52: 673-751.
21. Norton SA, Ruze P,. 1994. Kava dermopathy. J Am Acad Dermatol 31: 89-97.
22. Passante E, Frankish N,. 2009. The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell. Inflamm Res 58: 737-745.
23. Pepping J,. 1999. Kava: Piper methysticum. Am J Health Syst Pharm 56: 957-958, 960.
24. Pescitelli G, Bilia AR, Bergonzi MC, Vincieri FF, Di Bari L,. 2010. Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and beta-cyclodextrin inclusion complex. J Pharm Biomed Anal 52: 479-483.
25. Rowe A, Zhang LY, Ramzan I,. 2011. Toxicokinetics of kava. Adv Pharmacol Sci 2011: 326724.
26. Ruze P,. 1990. Kava-induced dermopathy: a niacin deficiency? Lancet 335: 1442-1445.
27. Rychetnik L, Madronio CM,. 2011. The health and social effects of drinking water-based infusions of kava: a review of the evidence. Drug Alcohol Rev 30: 74-83.
28. Sadofsky LR, Boa AN, Maher SA, Birrell MA, Belvisi MG, Morice AH,. 2011. TRPA1 is activated by direct addition of cysteine residues to the N-hydroxysuccinyl esters of acrylic and cinnamic acids. Pharmacol Res 63: 30-36.
29. Schmidt P, Boehncke WH,. 2000. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis 42: 363-364.
30. Shwayder T,. 2004. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 5: 17-29.
31. Singh YN,. 1992. Kava: an overview. J Ethnopharmacol 37: 13-45.
32. Smith CK, Moore CA, Elahi EN, Smart AT, Hotchkiss SA,. 2000. Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol. Toxicol Appl Pharmacol 168: 189-199.
33. Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H,. 2006. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18: 1584-1594.
34. Takayam K, Kajita T, Murata J, Tateshi Y,. 2006. Phylogeography and genetic structure of Hibiscus tiliaceus-speciation of a pantropical plant with sea-drifted seeds. Mol Ecol 15: 2871-2881.
35. Teschke R, Sarris J, Schweitzer I,. 2011. Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 73: 170-174.
36. Xuan TD, Fukuta M, Wei AC, Elzaawely AA, Khanh TD, Tawata S,. 2008. Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots. J Nat Med 62: 188-194.